{"entity":{"id":"haiti-dpm-mt","kind":"institution","name":"Direction de la Pharmacie, du Médicament et de la Médecine Traditionnelle (DPM/MT), Haiti","aka":["DPM/MT","DPM/MT-MSPP","Haiti medicines directorate"],"tldr":"The directorate of Haiti's health ministry that deals with medicines. It wrote the national essential medicines list, and the ministry publishes a register of medicines authorised in Haiti.","summary":"The Direction de la Pharmacie, du Médicament et de la Médecine Traditionnelle is a directorate of the Ministère de la Santé Publique et de la Population, not a separate agency. It designed and coordinated the second edition of the Liste Nationale des Médicaments Essentiels (January 2020), which lists 596 medicines in 30 therapeutic groups plus a complementary list of 139 products; its cancer medicines, from cytotoxics such as cisplatin, doxorubicin and paclitaxel to imatinib, rituximab, trastuzumab and tamoxifen, are listed for use at tertiary level, in university and specialised hospitals. The list was prepared with WHO experts and GHSC-PSM/USAID and recommends that facilities buy generics. The coordinates are an approximate Port-au-Prince city point.\n\nThe Ministry's website publishes a register of authorised medicines; on 11 November 2026 it held 1,178 products, listed by name, pack, form and strength without dates. A search of it by name found few cancer medicines: tamoxifen, anastrozole, letrozole, bicalutamide, goserelin, imatinib, fluorouracil, methotrexate and zoledronic acid. Haiti does not appear on WHO's list of regulators operating at maturity level 3 or 4 (August 2026).","asOf":"2026-11-11","links":[{"label":"MSPP: médicaments autorisés (register)","url":"https://mspp.gouv.ht/medicaments-autorises"},{"label":"MSPP: Liste Nationale des Médicaments Essentiels, 2nd edition, January 2020 (PDF)","url":"https://www.mspp.gouv.ht/sites/default/files/2025-12/Liste%20Nationale%20des%20M%C3%A9dicaments%20Essentiels%202e%20%C3%A9dition_publication%202022%20%281%29.pdf"},{"label":"WHO: list of regulatory authorities operating at maturity level 3 and 4 (August 2026)","url":"https://www.who.int/publications/m/item/list-of-nras-operating-at-ml3-and-ml4"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["haiti-mspp"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Port-au-Prince","country":"HT","lat":18.54,"lng":-72.33,"institutionType":"government","website":"https://mspp.gouv.ht/medicaments-autorises","programs":["Liste Nationale des Médicaments Essentiels (2nd edition, January 2020)","Register of authorised medicines","Formulaire Thérapeutique National"]},"route":"/institutions/haiti-dpm-mt/","neighbours":{"institution":[{"id":"haiti-mspp","kind":"institution","name":"Ministère de la Santé Publique et de la Population, Haiti","route":"/institutions/haiti-mspp/"}]}}